Vantictumab (Anti-FZD)
Product Specifications
CAS Number
1345009-45-1
Synonyms
OMP-18R5
Target
Wnt/beta-catenin
Applications
Cytoskeletal Signaling
Additionnal Information
Vantictumab (Anti-FZD) is a monoclonal antibody targeting the Wnt signaling pathway with potential antineoplastic activity. Vantictumab binds to certain receptors in the Wnt signaling pathway thereby preventing the activation of the Wnt signaling pathway. This results in an inhibition of cancer stem cell (CSC) activity and a subsequent inhibition of cancer cell proliferation. MW: 145.5 KD.
Storage Conditions
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC740031-500 1x 500 µL
Mucin 5AC (MUC5AC) (45M1), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC681879-100 1x 100 µL
Bcl-2 (Apoptosis & Follicular Lymphoma Marker) (rBCL2/796), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC401920-500 1x 500 µL
CDX2 / Caudal Type Homeobox 2 (GI Epithelial Marker) (PCRP-CDX2-1A3), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC401071-100 1x 100 µL
Ksp-Cadherin / CDH16 (CDH16/1071), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC042809-500 1x 500 µL
CELA3B / ELA3B (Pancreatic Function Marker) (CELA3B/2809R), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details